Aaron Kantoff
Aaron Kantoff is a founder and Managing Partner of Scion Life Sciences. Over the past 15 he has specialized in founding, building and investing in life sciences companies, focusing primarily on therapeutics.
Mr. Kantoff currently serves as a board member of Avalo Therapeutics (NASDAQ: AVTX), and previously served as a Venture Partner at Medicxi, where he was a founding board member of Centessa Pharmaceuticals PLC (NASDAQ: CNTA), recently acquired by Eli Lilly (NASDAQ: LLY). Prior to launching Scion, he was a co-founder and founding board member of RayzeBio, which was acquired by Bristol Myers Squibb (NYSE: BMY). Before that, Mr. Kantoff was a Partner at Apple Tree Partners (ATP), a life sciences venture capital firm, where he played a leading role in assembling several ATP portfolio companies, serving on the boards of Akero Therapeutics (NASDAQ: AKRO, acquired by Novo Nordisk), Corvidia Therapeutics (acquired by Novo Nordisk) and Syntimmune (acquired by Alexion), as well as two privately held companies (Marengo and Ascidian). During his time at ATP, Aaron was also a board observer at Stoke Therapeutics (NASDAQ: STOK) and led many of ATP’s crossover and public biotech investments. Before joining ATP in 2011, Aaron held various roles in private equity and investment banking.
Mr. Kantoff received a BS in finance and international business from NYU’s Stern School of Business.